Skip to content

Study · Not a test of the peptide alone · 2007

3 results

Studies of bioactivity, conformation and pharmacokinetic profiles of site-specific PEGylated thymosin alpha 1 derivatives.

Qie J, Ma J, Wang L, Xu X, Zheng J, Dong S, Xie J, Sun H, Zhou W, Qi C, Zhao X, Zhang Y, Liu K

Drug metabolism letters1 Aug 2007Cited by 1 (Europe PMC)

PMID19356048 (opens in a new tab)DOI10.2174/187231207781369780 (opens in a new tab)PepBankPUB-19356048
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneOther designPharmacokinetics

    PEGylation site and region influenced the pharmacokinetic profiles of thymosin alpha‑1 derivatives greatly, in the order alpha-helix, beta-turn, random coil and terminals.

    In plain wordsThe site where polyethylene glycol was attached changed how thymosin alpha‑1 derivatives behaved in the body over time.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedPharmacokinetic profile of PEGylated derivatives
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Results demonstrated that PEGylated sites and regions influenced the conformations and pharmacokinetic profiles of the peptide greatly with following order: alpha-helix, beta-turn, random coil and terminals, but little on the immunoactivity.
    1 context sentence
    Summary · context
    Site-specific mono-PEGylations were performed in different conformational regions of Thymosin alpha 1 (T alpha 1) by introducing one cysteine residue into the chosen site and coupling with thiol-specific mPEG-MAL reagent.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Mechanism

    PEGylation site and region influenced the conformation of thymosin alpha‑1 derivatives greatly, in the order alpha-helix, beta-turn, random coil and terminals.

    In plain wordsIn lab tests, the site where polyethylene glycol was attached changed the shape of thymosin alpha‑1 derivatives a lot.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedConformation of PEGylated derivatives
    Study

    n: not reported in source

    site-specific mono-PEGylated thymosin alpha 1 derivatives
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Results demonstrated that PEGylated sites and regions influenced the conformations and pharmacokinetic profiles of the peptide greatly with following order: alpha-helix, beta-turn, random coil and terminals, but little on the immunoactivity.
    1 context sentence
    Summary · context
    Site-specific mono-PEGylations were performed in different conformational regions of Thymosin alpha 1 (T alpha 1) by introducing one cysteine residue into the chosen site and coupling with thiol-specific mPEG-MAL reagent.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03LabNot a test of Thymosin alpha-1 aloneOther designActivity measurement

    PEGylation site and region had little influence on the immunoactivity of thymosin alpha‑1 derivatives.

    In plain wordsIn lab tests, attaching polyethylene glycol at different sites changed the immune activity of thymosin alpha‑1 derivatives only a little.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeImmunoactivity of PEGylated derivatives
    Study

    n: not reported in source

    site-specific mono-PEGylated thymosin alpha 1 derivatives
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Results demonstrated that PEGylated sites and regions influenced the conformations and pharmacokinetic profiles of the peptide greatly with following order: alpha-helix, beta-turn, random coil and terminals, but little on the immunoactivity.
    1 context sentence
    Summary · context
    Site-specific mono-PEGylations were performed in different conformational regions of Thymosin alpha 1 (T alpha 1) by introducing one cysteine residue into the chosen site and coupling with thiol-specific mPEG-MAL reagent.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.